The activity of compound 4 was previously attributed to EZH2 inhibition, likely due to the importance of EZH2-containing polycomb repressive complex 2 (PRC2) as well as the observation of EZH2-overexpression in many types of cancers [44–46]. The gene discussed is EZH2; the disease is cancer.